Srinivasan Murali Presents SmartCardia at LSI Europe '23

SmartCardia's 7L Patch is a wearable 7-lead electrocardiogram (ECG) patch for cardiology and remote patient monitoring.
Srinivasan Murali
Srinivasan Murali
CEO, SmartCardia



Srinivasan Murali  0:03  
Good afternoon everyone. I'm Srini Murali, CEO and co founder of SmartCardia. I'm happy to present you our company. SmartCardia offers live patient monitoring, with multi lead ECG, and a comprehensive set of vitals all from a single wearable patch. Our solution is disrupting the cardiac monitoring industry. So our solution has CE approvals and is widely used in our 100 Plus hospitals and by used by clinicians in Europe and globally. And just this week, we received our FDA approvals and we are entering the US market very soon. If you look at the cardiac and remote patient monitoring, it's a $30 billion market opportunity. The market is segmented into three different areas. So one is cardiac screening. The patients are monitored from 24 hours to 30 days with cardiac patches and wired monitors. Then you have Ward and post discharge monitoring where patients are monitored and cardiac wards and patients are discharged home and you have this hospital at Home program where more and more patients are sent back home earlier. And the last is rpm or remote patient monitoring, which we are all familiar with, where a variety of devices were used to monitor patients with chronic conditions from months to years. SmartCardia's patch technology covers the entire spectrum from screening to post discharge to remote patient monitoring. And all of this is very well reimbursed. If you look at cardiac screening, it is about few $100 per patient up to a few $1,000 that can be built with current CPT codes. With RPM, we can go up to $1,500 per patient per year. And for Ward and post discharge monitoring, there's significant cost savings for the hospital system in discharging patients early. And this is a growing market only the screening market. If you look at the numbers today, there are about 6 million screening tests performed each year in the US alone. And the numbers are equal. If you look at other countries like Europe or other major markets as well, this number is rapidly increasing. With more predictive algorithms and predictive screening. This number is going to go from 6 million to 20 to 25 million. And there are significant adjacent market opportunities for which our patch technology also works really well like sleep apnea, heart failure and hypertension. Thanks to the measurement of multiple vitals that are important to detect all these other conditions as well. All from a single patch, or single patch is a seven lead ECG patch that stays on the patient's skin for 14 days. The patch measures ECG heart rate, it also measures oxygen saturation, respiration, temperature, posture and activity. And all of this data is transmitted live. So a clinician or a hospital can see the ECG and the vitals coming live, or integrated AI platform directly looks at all this data and crunches meaningful information and reports to the cardiologist or the clinician when a patient is having a particular rabbit meow or deterioration. The patch is skin friendly waterproof, a single patch can stay on for 14 days, the sensor is reusable. So a same patient can be monitored for 30 days or longer by having multiple low cost disposable patches with reusable sensor. And we saw the major challenges that physicians are facing today in the cardiology practice. So what are the top five physician needs when you look at patient monitoring? First one is accurate multi lead ECG monitoring. in cardiology practice, cardiologists went from single lead wire devices to five to seven lead wire devices over a span of 20 30 years from the 1970s to the 1990s. When you look at purchase today, they're all single lead and clinicians very well know that single lead you have limited accuracy in detecting arrhythmias. And if you want to go beyond arythmia especially looking at patients having chest pain, ST elevation. For this you require a true multiline very have reciprocal ECG leads. The second challenge today, most solutions in the market are not live monitoring. So the most widely use patch as a store is only it takes anywhere between three to four weeks from a clinician seeing a patient to getting a PDF report on exactly what's happening to the patient. The third one is clinicians need a long term wearable patch. So recent data has shown that monitoring patients for 14 days provides the highest yield in terms of arrhythmia monitoring. The final two points, clinicians cardiologists also want to get I just want information from other sensing modalities. For example, if they know what happens to the patient's respiration rate or when a patient is having an oxygen saturation drop, then they can know if deserted me is related to sleep apnea or as related to the heart. The final point which is most interesting is low cost of operation easy to use. Today's cardiac patches are difficult to operate. So either they are disposable electronic patches which are expensive. All the electronics is refurbished at a technician center. So at SmartCardia, we have solved all these big issues with current solutions with our wearable patch. So patch transmits the data through the patient's mobile phone, and transmits directly all of this information to the cloud, our integrated AI platform caught arrhythmia as in real time, and notifies clinicians when significant added me as a present, or AI algorithms also allow the clinicians to quickly analyze the data and provides a SaaS platform where clinicians can access data quickly, they can also see what happened to a patient few minutes before a particular cardiac event fairly easily, which is difficult today with current solutions, or AI algorithms have been validated to achieve cardiologists level accuracy in detecting and predicting cardiac arrhythmias. So all of this data streams live. So this is similar to what you see in like ICU monitors, but completely scalable 1000s of patients. At the same time, you don't need nursing staff or cardiologists looking at the screen life because all of these are automatically triggered to the clinician when the information is meaningful. So we have strong IP. So we have seven patients, most of which are already granted in the US covering the different aspects of the technology from sensor fusion from the AI methods, and the ability to detect different bio signals. And we were also recognized by Frost and Sullivan in 2022. As the global leader in the ECG patch, and wearable space, the two particular lines from Frost and Sullivan epitomizes what SmartCardia stands for one is the multi vital, and the other is the AI to uniquely look at all these different insights coming from the different vitals as well as the ECG in predicting the patient health. So we started commercialization around 2017. Before that, we were in research phase. So we have a first generation product, which is a single lead ECG product, which has been in the UK in the European market for the past two years. We completed our series, a financing and seed financing in 2020. So far, we have raised about 13 million US dollars. So currently, we are raising Series B round of financing of 15 million US dollars for our US commercialization, and most of it is already committed by investors. So solution is well proven, we have over 10 clinical studies validating the different aspects of the technology in 3000 Plus patients in global trials. 100 Plus hospitals are using our solution globally. And many of these parameters that we obtain like which are difficult to get like the oxygen saturation from peripheral part in the body. All of this has been validated from leading institutions in the US and globally. We have a very strong technical team as well as clinical and execution team. My background, I have a PhD from Stanford and electronics, I sold my first company in the semiconductor space, I was part of a IMEC, a team that built some of the earliest ECG patches. And that's when I got into the space. And the IMEC technology is powering millions of patient care patient monitoring patches in the US today. We have a strong execution team in the US as well. So we have Adam joining from Bardy Diagnostics, who has scaled the body sales for patch monitoring in the US. And also we have top advisory team coming from Bardy Diagnostics either than by hotel and backing off top clinicians globally from Harvard and top institutes in the US and globally. Thank you

LSI Europe ‘24 is filling fast. Secure your spot today to join Medtech and Healthtech leaders.

September 16-20, 2024 The Ritz-Carlton - Sintra, Portugal Register arrow